PedvaxHIB

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline, Johns Hopkins Bloomberg School of Public Health

Conditions

Haemophilus Influenzae Type B InfectionHaemophilus Influenzae Type bNeisseria Meningitidis

Phase 3

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

CompletedNCT00289783

GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis

Start: 2006-02-22End: 2008-02-26Updated: 2018-08-24

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

CompletedNCT00345683

GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis

Start: 2007-07-31End: 2008-11-30Updated: 2016-11-29

Phase 4

Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)

CompletedNCT04978818

Johns Hopkins Bloomberg School of Public HealthHaemophilus Influenzae Type B Infection

Start: 2022-01-27End: 2023-10-26Updated: 2024-06-24

Related Papers

Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials.

2012-08-017 citations

The safety profile of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY).

2012-02-139 citations